Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**BENEFICIAL OWNERSHIP** 

STATEMENT OF CHANGES IN
-------------------------

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Christmas Patrick J.							2. Issuer Name and Ticker or Trading Symbol REGENXBIO Inc. [ RGNX ]									cable) or (give title	g Pers	10% Ov Other (s	/ner
(Last) (First) (Middle) C/O REGENXBIO INC. 9600 BLACKWELL ROAD, SUITE 210						3. Date of Earliest Transaction (Month/Day/Year) 12/31/2018									below) below) SVP, General Counsel				
(Street) ROCKVILLE MD 20850 (City) (State) (Zip)					_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)									ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		Tab	le I - N	Non-Deri	ivativ	e Sec	curities	s Ac	cquired,	D	isposed o	f, or B	enefic	ially	Owned	]			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye						Execut		<i>'</i>	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			Benefi Owned		ies Fe cially (E Following (I)		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership
									Code V A		Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock <sup>(1)</sup> 12/31/201						18			A		337	Α	\$35.6	6575 <sup>(2)</sup> 3,		3,006		D	
		-	Table I								posed of, , converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amou or Numb of Share	per					
Stock Option	\$40.82	01/03/2019			A		45,000		(3)		01/03/2029	Commo	<sup>n</sup> 45,0	00	\$0.00	45,000	)	D	

## **Explanation of Responses:**

- 1. The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2018 through December 31, 2018. This transaction is exempt under Rule 16b-3(c).
- 2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2018.
- 3. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer.

## Remarks:

/s/ Patrick J. Christmas

\*\* Signature of Reporting Person Date

01/07/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.